Recro Pharma Inc Expected to Earn Q2 2019 Earnings of ($0.33) Per Share (REPH)

Recro Pharma Inc (NASDAQ:REPH) – Research analysts at Oppenheimer cut their Q2 2019 EPS estimates for Recro Pharma in a research note issued on Monday, May 13th. Oppenheimer analyst L. Gershell now anticipates that the specialty pharmaceutical company will post earnings of ($0.33) per share for the quarter, down from their previous forecast of ($0.23). Oppenheimer has a “Outperform” rating and a $15.00 price objective on the stock. Oppenheimer also issued estimates for Recro Pharma’s Q3 2019 earnings at ($0.06) EPS, Q4 2019 earnings at $0.07 EPS, FY2019 earnings at ($0.41) EPS, FY2020 earnings at $0.76 EPS, FY2021 earnings at $0.88 EPS, FY2022 earnings at $1.00 EPS and FY2023 earnings at $1.17 EPS.

Recro Pharma (NASDAQ:REPH) last released its quarterly earnings data on Friday, May 10th. The specialty pharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.79) by $0.69. The company had revenue of $25.07 million for the quarter, compared to analysts’ expectations of $20.51 million. Recro Pharma had a negative net margin of 83.56% and a negative return on equity of 654.93%.



Other equities analysts have also recently issued research reports about the stock. ValuEngine cut shares of Recro Pharma from a “buy” rating to a “hold” rating in a research report on Monday, March 25th. Zacks Investment Research raised shares of Recro Pharma from a “hold” rating to a “buy” rating and set a $9.25 price target on the stock in a research report on Wednesday, April 24th. Roth Capital reaffirmed a “neutral” rating and issued a $7.50 price target (down previously from $15.00) on shares of Recro Pharma in a research report on Monday, March 25th. Finally, Janney Montgomery Scott reiterated a “buy” rating and issued a $13.00 price objective on shares of Recro Pharma in a research note on Thursday, January 31st. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Recro Pharma has a consensus rating of “Buy” and a consensus target price of $10.95.

Shares of NASDAQ REPH opened at $8.99 on Thursday. Recro Pharma has a fifty-two week low of $4.78 and a fifty-two week high of $13.05. The stock has a market capitalization of $203.28 million, a P/E ratio of -3.61 and a beta of -0.13. The company has a current ratio of 3.56, a quick ratio of 2.08 and a debt-to-equity ratio of 4.04.

In other Recro Pharma news, CEO Geraldine Henwood sold 144,806 shares of the stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $8.89, for a total value of $1,287,325.34. Following the completion of the sale, the chief executive officer now owns 342,947 shares in the company, valued at approximately $3,048,798.83. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 20.10% of the company’s stock.

Several hedge funds have recently modified their holdings of REPH. Renaissance Technologies LLC increased its stake in shares of Recro Pharma by 26.0% during the 3rd quarter. Renaissance Technologies LLC now owns 480,500 shares of the specialty pharmaceutical company’s stock worth $3,416,000 after purchasing an additional 99,200 shares during the last quarter. Oppenheimer & Co. Inc. increased its stake in shares of Recro Pharma by 5.5% during the 4th quarter. Oppenheimer & Co. Inc. now owns 32,313 shares of the specialty pharmaceutical company’s stock worth $229,000 after purchasing an additional 1,683 shares during the last quarter. Rhumbline Advisers increased its stake in shares of Recro Pharma by 47.8% during the 4th quarter. Rhumbline Advisers now owns 23,753 shares of the specialty pharmaceutical company’s stock worth $169,000 after purchasing an additional 7,679 shares during the last quarter. Essex Investment Management Co. LLC increased its stake in shares of Recro Pharma by 1.9% during the 4th quarter. Essex Investment Management Co. LLC now owns 257,707 shares of the specialty pharmaceutical company’s stock worth $1,830,000 after purchasing an additional 4,833 shares during the last quarter. Finally, Monarch Partners Asset Management LLC increased its stake in shares of Recro Pharma by 57.4% during the 4th quarter. Monarch Partners Asset Management LLC now owns 55,857 shares of the specialty pharmaceutical company’s stock worth $397,000 after purchasing an additional 20,367 shares during the last quarter. Institutional investors own 56.12% of the company’s stock.

Recro Pharma Company Profile

Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.

Further Reading: Investing in Growth Stocks

Earnings History and Estimates for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.